Clopidogrel

How to order Clopidogrel

1. Find the drug you need on our site.
2. Pick a clinic. See the price.
3. Fill in a short health form.
4. A doctor reads your form.
5. If it is safe for you, they say yes.
6. Your order ships fast to your door.
7. It comes in a plain, sealed box.

Why use us? We compare UK clinics. We show you the price and how fast they ship. We do not sell drugs. We just help you find the best one for you.

Is it safe? Yes. All our clinics are UK-based. A real doctor reads each form. They will not sell to you if it is not safe for you.

Clopidogrel on Prescriptsy

Clopidogrel is described on Prescriptsy as independent product information.

Here you can understand how online consultation works, what medical checks partner clinics carry out, and which factors matter when comparing providers.

We do not sell medicines directly, but help users compare licensed healthcare partners on price, delivery speed, service quality, and overall trustworthiness.

Clopidogrel is an antiplatelet medicine belonging to the thienopyridine class, widely prescribed in the United Kingdom for the secondary prevention of atherothrombotic events.

It works by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on platelets, reducing platelet aggregation and lowering the risk of arterial thrombosis.

Clopidogrel is used in patients who have experienced a myocardial infarction (heart attack), ischaemic stroke, or who have established peripheral arterial disease (PAD).

It is also a key component of dual antiplatelet therapy (DAPT), prescribed in combination with aspirin after percutaneous coronary intervention (PCI) with stenting and during the management of acute coronary syndromes.

Cardiovascular disease remains the leading cause of death worldwide and accounts for approximately 27% of all deaths in the UK.

Effective secondary prevention with antiplatelet therapy is one of the most evidence-based interventions in modern cardiology, significantly reducing the recurrence of heart attacks, strokes, and cardiovascular death.

This page provides a comprehensive clinical overview of clopidogrel, including its mechanism of action, licensed indications, dosing guidance, side effects, important warnings about bleeding and drug interactions, and information about obtaining a prescription in the UK.

Important safety information about clopidogrel

Before reading further, note the following critical safety points about clopidogrel.

• Clopidogrel increases the risk of bleeding. Inform all healthcare professionals (including dentists and surgeons) that you are taking clopidogrel before any procedure.
• Do not stop clopidogrel without medical advice. Premature discontinuation, particularly in patients with recent coronary stents, can lead to stent thrombosis, which is a life-threatening emergency.
• Avoid omeprazole and esomeprazole, which may reduce the effectiveness of clopidogrel. Lansoprazole or pantoprazole are preferred if gastroprotection is needed.
• Seek immediate medical attention for any signs of unusual or prolonged bleeding, including blood in stools or urine, black tarry stools, vomiting blood, or severe headache.

What is secondary cardiovascular prevention

Secondary prevention refers to the medical strategy of reducing the risk of further cardiovascular events in people who have already experienced a heart attack, stroke, or who have established atherosclerotic vascular disease.

It involves a combination of lifestyle modifications (stopping smoking, healthy diet, regular exercise, weight management) and pharmacological treatments including antiplatelet therapy, statins, blood pressure management, and diabetes control.

Antiplatelet agents such as clopidogrel are a cornerstone of this strategy, as arterial thrombosis (clot formation in diseased arteries) is the immediate cause of most heart attacks and ischaemic strokes.

Cardiovascular disease in the UK

According to the British Heart Foundation, there are approximately 7.6 million people living with cardiovascular disease in the UK.

Coronary heart disease alone causes around 64,000 deaths per year, and stroke causes approximately 36,000 deaths per year.

Effective secondary prevention, including antiplatelet therapy, has contributed to a significant decline in cardiovascular mortality over recent decades, but cardiovascular disease remains the second leading cause of death in the UK after cancer.

How clopidogrel works: mechanism of action

Clopidogrel is an inactive prodrug that requires hepatic biotransformation to generate its active thiol metabolite.

After oral absorption, approximately 85% of the dose is hydrolysed by esterases to an inactive carboxylic acid derivative.

The remaining 15% undergoes a two-step oxidative process, primarily catalysed by cytochrome P450 enzymes CYP2C19 and CYP3A4, to produce the active metabolite.

This active metabolite forms a disulphide bridge with a cysteine residue on the P2Y12 ADP receptor on the platelet surface, irreversibly blocking ADP-mediated platelet activation.

ADP is one of the key physiological agonists of platelet aggregation.

When ADP binds to the P2Y12 receptor, it triggers a signalling cascade that activates the glycoprotein IIb/IIIa receptor, the final common pathway for platelet aggregation via fibrinogen cross-linking.

By blocking P2Y12, clopidogrel prevents this cascade, reducing platelet aggregation and thrombus formation at sites of arterial plaque rupture or stent deployment.

Because the binding is irreversible, each platelet exposed to the active metabolite is inhibited for its entire remaining lifespan (approximately 7 to 10 days).

This means that the antiplatelet effect persists for several days after the drug is discontinued.

Clinically significant inhibition of platelet aggregation is observed within 2 hours of a 300 mg loading dose, and steady-state inhibition is reached after 3 to 7 days of daily maintenance dosing with 75 mg.

Licensed indications in the UK

The MHRA-approved indications for clopidogrel in the UK are as follows.

Acute coronary syndrome

Clopidogrel in combination with aspirin is indicated for patients with non-ST-segment elevation acute coronary syndrome (unstable angina or NSTEMI) and for patients with STEMI who are eligible for thrombolytic therapy.

NICE Technology Appraisal TA210 and TA236 provide guidance on the use of clopidogrel and other P2Y12 inhibitors in ACS.

In current UK practice, ticagrelor has largely replaced clopidogrel as the preferred P2Y12 inhibitor for ACS in patients undergoing PCI (based on the PLATO trial data), though clopidogrel remains appropriate for patients who cannot tolerate ticagrelor or prasugrel, or who are managed conservatively.

Percutaneous coronary intervention with stenting

DAPT with clopidogrel and aspirin is used to prevent stent thrombosis after coronary stent implantation.

The duration of DAPT depends on the type of stent (drug-eluting or bare-metal), the clinical context (ACS versus elective PCI), and the individual patient's bleeding risk.

Current ESC and NICE guidance recommend DAPT for 6 to 12 months after drug-eluting stent implantation in the context of ACS, with shorter durations (1 to 3 months) considered for patients at high bleeding risk.

Secondary prevention in stable atherosclerotic disease

Clopidogrel 75 mg daily is an alternative to aspirin for the long-term secondary prevention of atherothrombotic events in patients with established cardiovascular disease (previous MI, previous ischaemic stroke, or established PAD).

The CAPRIE trial demonstrated that clopidogrel was marginally superior to aspirin in reducing the composite endpoint of ischaemic stroke, MI, and vascular death, with a relative risk reduction of 8.7%.

NICE CG181 (Cardiovascular disease: risk assessment and reduction) recommends clopidogrel as an option for secondary prevention where aspirin is not tolerated.

Clinical evidence and guidelines

The landmark CAPRIE trial (1996) established clopidogrel as an effective antiplatelet agent for secondary prevention, demonstrating non-inferiority and a modest superiority to aspirin.

The CURE trial (2001) demonstrated that DAPT with clopidogrel and aspirin in NSTEMI reduced the composite of cardiovascular death, MI, and stroke by 20% compared with aspirin alone, at the cost of a modest increase in major bleeding.

The COMMIT trial (2005) confirmed benefit in STEMI patients treated with thrombolysis.

More recent trials (PLATO, TRITON-TIMI 38) have shown that newer P2Y12 inhibitors (ticagrelor and prasugrel) provide superior efficacy compared with clopidogrel in the ACS setting, which has shifted prescribing patterns in the UK.

However, clopidogrel remains widely prescribed due to its established safety profile, lower cost (generic availability since 2012), and suitability for patients at higher bleeding risk or those who cannot tolerate the newer agents.

NICE TA210, TA236, and CG181, together with the ESC guidelines on ACS and chronic coronary syndromes, inform current UK prescribing practice for clopidogrel.

The choice of antiplatelet agent is individualised based on clinical indication, bleeding risk, tolerability, and CYP2C19 metaboliser status where relevant.

Dosage and administration

The standard maintenance dose of clopidogrel is 75 mg once daily for all licensed indications.

A loading dose of 300 mg (or 600 mg before PCI) is used in acute settings to achieve rapid platelet inhibition.

Clopidogrel tablets should be taken at the same time each day, with or without food. No dose adjustment is required for elderly patients.

Limited data are available for patients with severe hepatic or renal impairment, and clonidine should be used with caution in these groups.

If you miss a dose, take it as soon as you remember on the same day.

If the entire day has passed, skip the missed dose and take the next one at the usual time. Never take a double dose.

If you are due for surgery, your prescriber will advise on whether and when to stop clopidogrel before the procedure.

Side effects of clopidogrel

Bleeding

Bleeding is the most significant and frequently reported adverse effect.

In the CAPRIE trial, the overall incidence of any bleeding event was approximately 9.3% with clopidogrel, compared with 9.3% with aspirin.

In the CURE trial, DAPT increased major bleeding compared with aspirin alone (3.7% versus 2.7%).

Bleeding can occur at any site, and patients should be vigilant for signs of unusual bruising, nosebleeds, blood in urine or stools, prolonged bleeding from cuts, and unexplained fatigue or pallor (which may indicate occult blood loss).

Gastrointestinal side effects

Dyspepsia, abdominal pain, diarrhoea, and nausea are commonly reported. Gastrointestinal haemorrhage, including peptic ulceration and bleeding, is an uncommon but clinically important adverse event.

Patients with a history of peptic ulcer disease should have gastroprotection with an appropriate PPI (avoiding omeprazole and esomeprazole due to the CYP2C19 interaction).

Haematological side effects

Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal complication that has been reported, usually within the first 2 weeks of treatment.

It is characterised by low platelet count, microangiopathic haemolytic anaemia (with fragmented red blood cells on blood film), renal impairment, fever, and neurological symptoms.

TTP requires immediate hospitalisation and plasma exchange. Other rare haematological effects include neutropenia, agranulocytosis, aplastic anaemia, and pancytopenia.

Other side effects

Headache, dizziness, and paraesthesia (tingling or numbness) have been reported uncommonly. Skin reactions including rash, pruritus, and urticaria are uncommon. Severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis) and hepatic adverse events (hepatitis, liver failure) are very rare.

When to seek medical advice

Contact your GP or NHS 111 for any unusual or unexplained bleeding, new bruising, blood in urine or stools, black tarry stools, unexplained tiredness, or skin rash.

Seek emergency care (call 999 or attend A&E) for severe or uncontrollable bleeding, vomiting blood, sudden severe headache (possible intracranial haemorrhage), signs of stroke, chest pain, or signs of TTP (unexplained bruising, fever, confusion, dark urine, reduced urine output).

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Warnings and precautions

Bleeding risk

Clopidogrel should be used with caution in patients at increased risk of bleeding, including those with recent surgery or trauma, active peptic ulcer disease, bleeding diathesis, or concomitant use of anticoagulants, NSAIDs, SSRIs, or other antiplatelet agents.

The bleeding risk must always be balanced against the thrombotic risk. Do not stop clopidogrel without medical advice, particularly if you have a coronary stent in place.

Surgical and dental procedures

If elective surgery is planned, discuss with your surgeon and prescriber whether to continue or temporarily stop clopidogrel.

The usual recommendation is to stop 5 to 7 days before major surgery to allow platelet function to recover.

For patients with recent coronary stents, premature discontinuation of DAPT carries a significant risk of stent thrombosis, and the decision must involve the treating cardiologist.

For minor dental procedures, clopidogrel can often be continued with local haemostatic measures.

CYP2C19 and drug interactions

Omeprazole and esomeprazole are moderate inhibitors of CYP2C19 and may reduce the antiplatelet efficacy of clopidogrel. If gastroprotection is needed, lansoprazole or pantoprazole should be used instead.

Genetic polymorphisms in CYP2C19 that reduce enzyme activity (poor metaboliser phenotype) may result in inadequate clopidogrel activation.

If you are known or suspected to be a CYP2C19 poor metaboliser, your prescriber may consider alternative P2Y12 inhibitors such as ticagrelor or prasugrel.

Other CYP2C19 inhibitors (fluconazole, fluoxetine, fluvoxamine, voriconazole) should be used with caution.

Pregnancy and breastfeeding

There are limited data on the use of clopidogrel during pregnancy.

It should be used only if clearly needed, and alternative antiplatelet strategies should be discussed with a cardiologist and obstetrician.

It is unknown whether clopidogrel is excreted in human breast milk. Breastfeeding should be discontinued during treatment.

How to get a clopidogrel prescription in the UK

Clopidogrel is a prescription-only medicine (POM) in the UK.

It is usually initiated by a hospital cardiologist, stroke physician, or vascular surgeon following a cardiovascular event or procedure, and continued by the patient's GP as part of their long-term secondary prevention regimen.

All UK prescriptions for clopidogrel are dispensed by registered pharmacies. Generic clopidogrel 75 mg tablets are widely available and cost-effective.

The standard NHS prescription charge in England is currently 9.90 pounds per item; prescriptions are free in Scotland, Wales, and Northern Ireland.

Living with cardiovascular disease: secondary prevention

Taking clopidogrel as prescribed is one part of a comprehensive approach to reducing your cardiovascular risk.

Other essential measures include taking all prescribed medications (statins, blood pressure medicines, diabetes treatment) as directed, stopping smoking (the single most impactful lifestyle change), eating a balanced diet rich in fruit, vegetables, whole grains, and oily fish while limiting saturated fat, salt, and processed food, taking regular physical activity as recommended by your cardiac rehabilitation team, maintaining a healthy weight, limiting alcohol intake, and attending regular follow-up appointments with your GP or cardiologist.

Cardiac rehabilitation programmes are offered by the NHS to patients recovering from heart attacks and coronary procedures. These structured programmes include supervised exercise, education, and psychological support, and have been shown to reduce cardiovascular mortality and improve quality of life.

When to seek urgent medical advice

Seek immediate medical help by calling 999 if you experience chest pain or tightness, symptoms of stroke (sudden weakness, numbness, speech difficulty, visual disturbance), severe or uncontrollable bleeding from any site, vomiting blood or passing black tarry stools, or sudden severe headache.

Contact your GP or NHS 111 for any unusual or unexplained bleeding, new or worsening bruising, blood in urine, persistent skin rash, or any new symptoms that concern you.

Report any suspected adverse reactions via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk .

Sources

• Clopidogrel 75 mg Film-Coated Tablets, Summary of Product Characteristics (EMC)
• Clopidogrel, British National Formulary (BNF)
• NICE TA210: Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events
• NICE CG181: Cardiovascular disease: risk assessment and reduction
• Coronary heart disease, NHS
• British Heart Foundation
• MHRA Yellow Card Scheme